NZ722492A - Specific biomarker set for non-invasive diagnosis of liver cancer - Google Patents

Specific biomarker set for non-invasive diagnosis of liver cancer

Info

Publication number
NZ722492A
NZ722492A NZ72249214A NZ72249214A NZ722492A NZ 722492 A NZ722492 A NZ 722492A NZ 72249214 A NZ72249214 A NZ 72249214A NZ 72249214 A NZ72249214 A NZ 72249214A NZ 722492 A NZ722492 A NZ 722492A
Authority
NZ
New Zealand
Prior art keywords
liver cancer
tumour
auto
antibodies
tumour antigens
Prior art date
Application number
NZ72249214A
Inventor
Bing Lou Wong
Cornelia Wing Yin Man
Norman Wai
Benjamin Wai
Original Assignee
Dragon Victory Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/321,867 external-priority patent/US9506925B2/en
Priority claimed from US14/321,870 external-priority patent/US9885718B2/en
Application filed by Dragon Victory Dev Ltd filed Critical Dragon Victory Dev Ltd
Publication of NZ722492A publication Critical patent/NZ722492A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Cells within liver tumour mass comprise a unique set of proteins/tumour antigens when compared to the normal liver tissues epithelial cells juxtaposed to the tumour. The presence of tumour antigens couples the production of auto-antibodies against these tumour antigens. The present invention relates to the identification and elucidation of a protein set that can act as a novel marker set for liver cancer diagnosis and prognosis. Specifically, it relates to a kit that enables diagnostic and prognostic measurement of auto-antibodies in serum of liver cancer patients. The present invention provides a non-invasive, specific, sensitive, and cost effective detection and quantification method by evaluating a set of validated liver cancer proteins/tumour antigens, which includes Bmi-1, VCC1, SUMO-4, RhoA, TXN, ET-1, UBE2C, HDGF2, FGF21, LECT2, SOD1, STMN4, Midkine, IL-17A or IL26, to complement the conventional diagnostic methods. In particular, the present invention relates to measuring auto-antibodies in serum of HCC patients against HDGF2.
NZ72249214A 2014-07-02 2014-07-31 Specific biomarker set for non-invasive diagnosis of liver cancer NZ722492A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/321,867 US9506925B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer
US14/321,870 US9885718B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer
PCT/US2014/049038 WO2016003479A1 (en) 2014-07-02 2014-07-31 Specific biomarker set for non-invasive diagnosis of liver cancer

Publications (1)

Publication Number Publication Date
NZ722492A true NZ722492A (en) 2019-09-27

Family

ID=55019816

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ72249214A NZ722492A (en) 2014-07-02 2014-07-31 Specific biomarker set for non-invasive diagnosis of liver cancer

Country Status (13)

Country Link
EP (1) EP3164711A4 (en)
JP (2) JP2017520763A (en)
KR (1) KR102086788B1 (en)
CN (2) CN107478842B (en)
AU (2) AU2014399919B2 (en)
CA (1) CA2939912C (en)
HK (2) HK1248803A1 (en)
MY (2) MY179845A (en)
NZ (1) NZ722492A (en)
SG (1) SG11201606106SA (en)
TW (1) TWI700493B (en)
UY (1) UY36200A (en)
WO (1) WO2016003479A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106383231B (en) * 2016-09-02 2020-03-17 四川大学 Marker combination for diagnosing liver cancer and application thereof
GB201619954D0 (en) * 2016-11-25 2017-01-11 Oncimmune Ltd Antibody assay
KR102175265B1 (en) 2019-03-13 2020-11-06 충남대학교산학협력단 Biomarker composition comprising TXNDC7 for diagnosis or predicting prognosis of hepatocellular carcinoma
CN110646615B (en) * 2019-08-27 2021-07-13 南方医科大学 Biological marker and treatment target of hepatic fibrosis and application thereof
WO2023282916A1 (en) 2021-07-09 2023-01-12 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
EP4407042A3 (en) 2020-07-10 2024-09-18 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
CN113502328A (en) * 2021-05-27 2021-10-15 深圳市人民医院 Application of reagent for detecting expression level of marker in sample in preparation of kit for detecting or diagnosing breast cancer
CN113777295B (en) * 2021-09-15 2024-03-19 江南大学 High-sensitivity quantum dot probe for detecting tumor marker PD-L1, preparation method and application
CN113956344A (en) * 2021-10-14 2022-01-21 江南大学 Novel FGF analogue for treating liver cancer and application thereof
CN114113611B (en) * 2021-12-13 2023-07-14 郑州大学 Biomarker for liver cancer diagnosis and detection kit

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6449562B1 (en) * 1996-10-10 2002-09-10 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
US6893844B1 (en) * 1998-09-22 2005-05-17 Long Yu DNA encoding a new human hepatoma derived growth factor and producing method thereof
US7387881B2 (en) * 2001-09-19 2008-06-17 The Regents Of The University Of Michigan Detection and treatment of cancers of the liver
AU2002361908A1 (en) * 2001-12-31 2003-07-24 Quark Biotech, Inc. Methods for identifying marker genes for cancer
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP3960614B2 (en) * 2003-08-31 2007-08-15 株式会社イムノディア Anti-peptide antibody measurement method and vaccine candidate selection method for peptide vaccine
GB0406215D0 (en) * 2004-03-19 2004-04-21 Procure Therapeutics Ltd Prostate stem cell
CA2567987A1 (en) * 2004-06-18 2005-12-29 Gabriele Pestlin Use of protein pdx1 as a marker for breast cancer
JP5211315B2 (en) * 2006-07-25 2013-06-12 国立大学法人愛媛大学 Tumor marker, tumor diagnostic kit, and method for measuring tumor marker
CN101796415B (en) * 2007-08-10 2014-03-12 学校法人兵库医科大学 Novel liver cancer marker
US8512963B2 (en) * 2009-11-25 2013-08-20 The Johns Hopkins University Detection and quantitation of full-length thioredoxin (TRX) and truncated thioredoxin (TRX 80) in complex samples
US9523680B2 (en) * 2010-06-30 2016-12-20 Ambergen, Inc. Global Proteomic screening of random bead arrays using mass spectrometry imaging
JP5493130B2 (en) * 2010-08-25 2014-05-14 国立大学法人山口大学 Autoantibody detection method
CN103492590A (en) * 2011-02-22 2014-01-01 卡里斯生命科学卢森堡控股有限责任公司 Circulating biomarkers
US20130130355A1 (en) 2011-09-28 2013-05-23 Armune Biosciences, Inc. Method and system of particle-phage epitope complex

Also Published As

Publication number Publication date
MY179845A (en) 2020-11-18
TW201602579A (en) 2016-01-16
JP2017520763A (en) 2017-07-27
SG11201606106SA (en) 2016-08-30
CN107478842A (en) 2017-12-15
EP3164711A1 (en) 2017-05-10
KR102086788B1 (en) 2020-03-09
AU2017232129B2 (en) 2018-10-25
UY36200A (en) 2016-01-29
CN107478842B (en) 2020-10-16
WO2016003479A1 (en) 2016-01-07
JP2020160082A (en) 2020-10-01
TWI700493B (en) 2020-08-01
MY195045A (en) 2023-01-04
EP3164711A4 (en) 2018-05-23
CA2939912A1 (en) 2016-01-07
HK1224370A1 (en) 2017-08-18
CN105319362A (en) 2016-02-10
AU2017232129A1 (en) 2017-10-12
CA2939912C (en) 2019-04-16
AU2014399919A1 (en) 2016-08-11
HK1248803A1 (en) 2018-10-19
AU2014399919B2 (en) 2019-10-24
KR20170021234A (en) 2017-02-27
CN105319362B (en) 2018-07-13

Similar Documents

Publication Publication Date Title
NZ722492A (en) Specific biomarker set for non-invasive diagnosis of liver cancer
MY188938A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder
MX2018008421A (en) Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies.
MX2021006791A (en) Methods and compositions for detecting misfolded proteins.
MX2018009304A (en) Diagnostic and prognostic methods for cardiovascular diseases and events.
MX2020001156A (en) Method for the prognosis and treatment of cancer metastasis.
EP3654036A3 (en) Stomach cancer biomarker and detection method
EP4282405A3 (en) Detection of cancer biomarkers using nanoparticles
MX2019000091A (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer.
IN2013CN01129A (en)
JP2014144959A5 (en)
EA201400117A1 (en) METHODS AND NUCLEIC ACIDS FOR DETERMINATION OF THE PREDICTION IN CANCER PATIENTS
WO2015176066A3 (en) Lpa-associated protein and rna expression
MX2023005452A (en) Amyloid beta detection by mass spectrometry.
WO2015082416A8 (en) Novel rna-biomarkers for diagnosis of prostate cancer
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
BR112016013976A2 (en) Method to determine if an individual is affected by a cancer, Method to discriminate between colorectal and pancreatic cancer among individuals who turn out to be positive for the method, Method to determine the stage of a colorectal cancer in an affected individual, and Use of an rt kit -pcr quantitative to perform the method
MX2016012278A (en) Early detection of preeclampsia.
SG10201806729VA (en) Novel assay to detect human periostin
WO2018187385A8 (en) Compositions and methods of diagnosing pancreatic cancer
CN106461665A8 (en) For diagnosis of pancreatic cancer including the kit for specifically binding to the antibody of complement factor B albumen and for specifically binding the antibody to the albumen of sugar antigen 19 9
IN2014DN08312A (en)
MX2017008748A (en) Assay to detect human dpp-4.
MX2019005940A (en) Biomarkers related to cancer.
WO2010142651A3 (en) Method for determining the risk of developing brain metastasis, and a kit to carry out said method

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: SPECIFIC BIOMARKER SET FOR NON-INVASIVE DIAGNOSIS OF LIVER CANCER; FILING DATE: 25 JUL 2016; STATUS: REJECTED; KIND CODE: A1 PUBLICATION DATE: 29 JUL 2016; TITLE: SPECIFIC BIOMARKER SET FOR NON-INVASIVE DIAGNOSIS OF LIVER CANCER; FILING DATE: 07 FEB 2018; STATUS: REJECTED; KIND CODE: TITLE: SPECIFIC BIOMARKER SET FOR NON-INVASIVE DIAGNOSIS OF LIVER CANCER; FILING DATE: 23 APR 2019; STATUS: REJECTED; KIND CODE: TITLE: SPECIFIC BIOMARKER SET FOR NON-INVASIVE DIAGNOSIS OF LIVER CANCER; FILING DATE: 09 MAY 2019; STATUS: REJECTED; KIND CODE: TITLE: SPECIFIC BIOMARKER SET FOR NON-INVASIVE DIAGNOSIS OF LIVER CANCER; FILING DATE: 16 SEP 2019; STATUS: PROPOSE

Effective date: 20190916

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2021 BY CPA GLOBAL

Effective date: 20200618

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2022 BY CPA GLOBAL

Effective date: 20210617

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2023 BY CPA GLOBAL

Effective date: 20220616

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2024 BY CPA GLOBAL

Effective date: 20230615